Knowledge Center

HPV and cervical cancer

HPV test to prevent cervical cancer

Human Papillomavirus (HPV) is one of the most common sexually transmitted infections. It is well known that the presence of HPV shows strong correlation with the incidence of tumors such as cervical carcinoma and its pre-cancerous states. HPV can be detected in almost 100% of cervical carcinoma patients.

Different HPV genotypes show different levels of risk to develop cervical carcinoma. According to the level of risk, there are low-risk and high-risk classes (groups) of genotypes.

The cumulative lifetime incidence of HPV infection is 70-80 percent in many countries. Most women who become infected with HPV are able to eradicate the virus and suffer no apparent long-term consequences, but a certain ratio develop a persistent infection that can lead to precancerous changes in the cervix.

The traditional screening process (PAP smear) to prevent cervical cancer has been performed with great success in the past decades. Nevertheless, women with negative PAP smear test results continue to develop cervical carcinoma.

The interest is growing worldwide to use HPV DNA test to adjunct cervical cancer prevention PAP smear programs. Combining these two methods can help eradicate the cancer of the cervix.

Furthermore, HPV DNA testing is the optimal way to determine the treatment after borderline PAP smear test results such as ASCUS (Atypical PAP or atypical squamous cells of undetermined significance).

The Benefit of PCR in Human Papillomavirus Detection

Overall there are approximately 100 genotypes of HPV. 50 out of these can cause infection in the genitalregion and 15 are known to be in the high-risk group. For high-quality patient management, it is required to detect all anogenital HPV and especially the high-risk genotypes.

A technology, that can fulfill these needs, has to be both highly sensitive and specific allowing precise discrimination of HPV types. Only one technology provides this outstanding set of features: PCR, which stands for polymerase chain reaction.

The polymerase chain reaction produces a billion copies of the target DNA sequence of the pathogen and even as few as ten copies of DNA can be detected.

On the basis of this technology GenoID manufactures two landmark HPV detection kits. The kits are the result of years of research and development and are based on the assay used in GenoID’s clinical laboratory where tens of thousands of HPV tests have been performed. Precise discrimination of the genotypes relies on a unique HPV DNA signature discovered by GenoID’s researchers.